First Canadian Participant Dosed in ARGUS Trial, A Phase 2 Potentially Pivotal Study of EPX-100 Treatment of Dravet Syndrome
June 01, 2022 04:00 ET | Epygenix Therapeutics
PARAMUS, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Epygenix Therapeutics, a clinical-stage biopharmaceutical company focused on genetically screening, discovering and developing safe, effective and...
Epygenix Therapeutics Announces Appointment of Dr. Lorianne Masuoka as Chief Medical Officer
May 23, 2022 04:00 ET | Epygenix Therapeutics
PARAMUS, N.J., May 23, 2022 (GLOBE NEWSWIRE) -- Epygenix Therapeutics, a clinical-stage biopharmaceutical company developing safe, effective, and patient-friendly drugs for rare and intractable...